Human Mesenchymal Stem Cell-Treated Regulatory CD23+CD43+ B Cells Alleviate Intestinal Inflammation
- PMID: 31367246
- PMCID: PMC6643430
- DOI: 10.7150/thno.32260
Human Mesenchymal Stem Cell-Treated Regulatory CD23+CD43+ B Cells Alleviate Intestinal Inflammation
Abstract
Rationale: Mesenchymal stem cells (MSCs) have been demonstrated to ameliorate inflammatory bowel disease by their actions on multiple immune cells, especially on regulatory B cells (Breg cells). However, the phenotypes and functions of human MSCs (hMSCs)-treated Breg cell subsets are not yet clear. Methods: Purified B cells were cocultured with MSCs and the phenotypes and immunomodulatory functions of the B cells were analyzed by FACS and proliferation assays in vitro. Also, a trinitrobenzenesulfonic acid-induced mouse colitis model was employed to detect the function of MSC-treated Breg cells in vivo. Results: We demonstrated that coculturing with hMSCs significantly enhanced the immunomodulatory activity of B cells by up-regulating IL-10 expression. We then identified that a novel regulatory B cell population characterized by CD23 and CD43 phenotypic markers could be induced by hMSCs. The CD23+CD43+ Breg cells substantially inhibited the inflammatory cytokine secretion and proliferation of T cells through an IL-10-dependent pathway. More significantly, intraperitoneal injection of hMSCs ameliorated the clinical and histopathological severity in the mouse experimental colitis model, accompanied by an increase in the number of CD23+CD43+ Breg cells. The adoptive transfer of CD23+CD43+ B cells effectively alleviated murine colitis, as compared with the CD23-CD43- B cells. Treatment with CD23+CD43+ B cells, and not hMSCs, substantially improved the symptoms of colitis in B cell-depleted mice. Conclusion: the novel CD23+CD43+ Breg cell subset appears to be involved in the immunomodulatory function of hMSCs and sheds new light on elucidating the therapeutic mechanism of hMSCs for the treatment of inflammation-related diseases.
Keywords: inflammatory bowel disease; interleukin-10; mesenchymal stem cells; regulatory B cells.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures









Similar articles
-
Immunomodulatory Effect of Urine-derived Stem Cells on Inflammatory Bowel Diseases via Downregulating Th1/Th17 Immune Responses in a PGE2-dependent Manner.J Crohns Colitis. 2020 Jun 19;14(5):654-668. doi: 10.1093/ecco-jcc/jjz200. J Crohns Colitis. 2020. PMID: 31841595
-
Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5(+) B regulatory cells.Stem Cell Res Ther. 2016 Aug 11;7(1):109. doi: 10.1186/s13287-016-0376-2. Stem Cell Res Ther. 2016. PMID: 27515534 Free PMC article.
-
IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut.J Autoimmun. 2014 May;50(100):107-22. doi: 10.1016/j.jaut.2014.01.032. Epub 2014 Feb 1. J Autoimmun. 2014. PMID: 24491821 Free PMC article.
-
The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells.Front Immunol. 2020 Aug 14;11:1843. doi: 10.3389/fimmu.2020.01843. eCollection 2020. Front Immunol. 2020. PMID: 32922398 Free PMC article. Review.
-
Regulatory B cells in infection, inflammation, and autoimmunity.Cell Immunol. 2020 Jun;352:104076. doi: 10.1016/j.cellimm.2020.104076. Epub 2020 Feb 27. Cell Immunol. 2020. PMID: 32143836 Review.
Cited by
-
Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Protect Liver Ischemia/Reperfusion Injury by Reducing CD154 Expression on CD4+ T Cells via CCT2.Adv Sci (Weinh). 2020 Aug 20;7(18):1903746. doi: 10.1002/advs.201903746. eCollection 2020 Sep. Adv Sci (Weinh). 2020. PMID: 32999825 Free PMC article.
-
Evaluation of feline mesenchymal stem cell susceptibility to feline viruses.Sci Rep. 2024 Aug 10;14(1):18598. doi: 10.1038/s41598-024-69343-1. Sci Rep. 2024. PMID: 39127765 Free PMC article.
-
Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties.Stem Cell Res Ther. 2024 Sep 27;15(1):320. doi: 10.1186/s13287-024-03943-6. Stem Cell Res Ther. 2024. PMID: 39334441 Free PMC article. Review.
-
Advances of Regulatory B Cells in Autoimmune Diseases.Front Immunol. 2021 Apr 15;12:592914. doi: 10.3389/fimmu.2021.592914. eCollection 2021. Front Immunol. 2021. PMID: 33936028 Free PMC article. Review.
-
Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.Stem Cells Transl Med. 2021 Sep;10(9):1288-1303. doi: 10.1002/sctm.21-0021. Epub 2021 May 19. Stem Cells Transl Med. 2021. PMID: 34008922 Free PMC article. Review.
References
-
- de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27. - PubMed
-
- Stappenbeck TS, Miyoshi H. The Role of Stromal Stem Cells in Tissue Regeneration and Wound Repair. Science. 2009;324:1666–9. - PubMed
-
- Barzilay R, Melamed E, Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem cells. 2009;27:2509–15. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources